UK markets closed

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.3850-0.0650 (-4.48%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 6.14M
Enterprise value 1.29M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.67
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.27

Trading information

Stock price history

Beta (5Y monthly) 0.38
52-week change 3-26.33%
S&P500 52-week change 322.36%
52-week high 32.3200
52-week low 30.6800
50-day moving average 31.3099
200-day moving average 31.2815

Share statistics

Avg vol (3-month) 311.82k
Avg vol (10-day) 312.81k
Shares outstanding 54.44M
Implied shares outstanding 64.44M
Float 83.22M
% held by insiders 121.83%
% held by institutions 17.96%
Shares short (15 Apr 2024) 49.83k
Short ratio (15 Apr 2024) 40.65
Short % of float (15 Apr 2024) 40.27%
Short % of shares outstanding (15 Apr 2024) 40.22%
Shares short (prior month 15 Mar 2024) 412.22k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 327 Jul 2016
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 323 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-45.78%
Return on equity (ttm)-94.48%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -4.5M
Net income avi to common (ttm)-5M
Diluted EPS (ttm)-1.1500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.06M
Total cash per share (mrq)0.92
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)6.41
Book value per share (mrq)0.83

Cash flow statement

Operating cash flow (ttm)-3.7M
Levered free cash flow (ttm)-2.47M